

ACL Laboratories COVID-19 and Influenza Activity Report


Updated: Dec 5, 2021



RESPIRATORY PATHOGEN PANEL Dec 5, 2021 Positivity Rate (%)



| MONTH | FLU A | FLU A (H1N1) | 2009 H1N1 | FLU A H3N2 | FLU B | RSV A | RSV B | RSV A/B | PARA 1 | PARA 2 | PARA 3 | Para 4 | COR 229E | COR NL63 | COR OC43 | COR HKU1 | META | E/R | Adeno | BOCA | Legio nella | Chla mydia | Mycoplasma |
|-------|-------|--------------|-----------|------------|-------|-------|-------|---------|--------|--------|--------|--------|----------|----------|----------|----------|------|------|-------|------|-------------|------------|------------|
| JAN | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 7.1 | 0.7 | 0.3 | 0.0 | 0.0 | 0.0 |
| FEB | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 0.0 | 0.0 | 0.2 | 6.1 | 0.2 | 0.3 | 0.0 | 0.0 | 0.0 |
| MAR | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.3 | 0.4 | 0.1 | 0.1 | 0.3 | 0.1 | 1.4 | 0.9 | 0.1 | 0.4 | 12.2 | 1.2 | 0.3 | 0.0 | 0.1 | 0.1 |
| APR | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.2 | 0.5 | 0.0 | 0.0 | 2.5 | 2.9 | 0.0 | 0.8 | 15.3 | 1.4 | 1.2 | 0.0 | 0.0 | 0.0 |
| MAY | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.7 | 3.9 | 0.0 | 0.2 | 1.4 | 3.9 | 0.0 | 0.0 | 14.4 | 1.7 | 1.4 | 0.2 | 0.0 | 0.1 |
| JUN | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 1.8 | 1.9 | 0.0 | 0.3 | 9.6 | 0.0 | 0.3 | 0.4 | 2.4 | 0.0 | 0.1 | 15.8 | 1.1 | 1.8 | 0.0 | 0.0 | 0.1 |
| JUL | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | 7.2 | 8.2 | 0.1 | 0.5 | 12.9 | 0.0 | 0.1 | 0.4 | 1.4 | 0.0 | 0.5 | 18.9 | 1.6 | 4.4 | 0.4 | 0.0 | 0.0 |
| AUG | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.8 | 12.5 | 13.3 | 0.0 | 1.2 | 6.2 | 0.1 | 0.1 | 0.1 | 0.5 | 0.0 | 0.7 | 14.0 | 1.3 | 3.6 | 0.0 | 0.0 | 0.0 |
| SEP | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 10.6 | 11.3 | 0.0 | 0.9 | 1.8 | 0.4 | 0.0 | 0.0 | 0.4 | 0.0 | 0.6 | 23.6 | 0.8 | 4.1 | 0.1 | 0.0 | 0.1 |
| OCT | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 | 7.3 | 7.8 | 0.0 | 1.6 | 1.2 | 1.0 | 0.1 | 0.0 | 0.4 | 0.0 | 0.3 | 21.0 | 1.2 | 4.0 | 0.2 | 0.0 | 0.0 |
| NOV | 0.0 | 0.1 | 0.1 | 0.7 | 0.0 | 0.3 | 7.3 | 7.6 | 0.1 | 1.5 | 0.9 | 1.5 | 0.2 | 0.1 | 0.9 | 0.0 | 1.0 | 18.3 | 1.4 | 3.7 | 0.1 | 0.0 | 0.0 |
| DEC | 0.0 | 0.0 | 0.0 | 2.7 | 0.0 | 0.0 | 5.8 | 5.8 | 0.0 | 0.4 | 1.6 | 1.9 | 0.0 | 0.0 | 0.8 | 0.0 | 1.6 | 12.8 | 1.2 | 5.4 | 0.0 | 0.0 | 0.0 |

Increased prevalence of viruses: **Rhinovirus, RSV, Boca virus, Parainfluenza 2,4 and Flu A**



ACL RSV positivity rate - trends down

CDC Data RSV pos rate for Region 5 Chicago - (PCR – 10%↓, Antigen - 10% ↓)




CDC RSV positivity rate - trends down

| SARS-COV-2 | | | | | Influenza PCR | | RSV PCR | | Hologic Aptima | |
|------------|-------------|-------------|------------|------------|---------------|-------------|-------------|-------------|----------------|------------|
| Week | IL % SCVPCR | WI % SCVPCR | IL % COVAG | WI % COVAG | IL % FLUPCR | WI % FLUPCR | IL % RSVPCR | WI % RSVPCR | IL % COV19 | WI % COV19 |
| Dec 5 | 11.1 | 11.3 | 13.5 | 22.7 | 5.5 | 5.5 | 5.1 | 6.0 | 6.3 | 11.6 |
| Nov 28 | 8.8 | 10.6 | 12.8 | 18.9 | 3.9 | 1.8 | 10.2 | 9.8 | 6.1 | 11.4 |
| Nov 21 | 5.8 | 10.3 | 8.5 | 20.2 | 1.9 | 0.2 | 14.0 | 12.0 | 3.8 | 9.6 |
| Nov 14 | 4.7 | 9.0 | 7.5 | 21.7 | 0.5 | 0 | 15.0 | 15.7 | 3.8 | 9.6 |
| Nov 7 | 3.8 | 7.4 | 6.6 | 17.6 | 0 | 0.3 | 21.4 | 20.7 | 3.2 | 7.8 |
| Oct 31 | 3.8 | 6.3 | 4.8 | 13.7 | 0.3 | 0 | 20.9 | 32.2 | 1.9 | 7.1 |
| Oct 24 | 3.7 | 5.6 | 5.1 | 16.7 | 0 | 0.2 | 22.5 | 30.6 | 2.2 | 7.0 |
| Oct 17 | 3.7 | 6.5 | 7.0 | 18.0 | 0 | 0 | 27.0 | 31.3 | 2.8 | 9.1 |
| Oct 10 | 4.3 | 7.6 | 5.0 | 18.2 | 0 | 0.2 | 23.9 | 32.6 | 2.2 | 9.7 |
| Oct 3 | 5.0 | 8.6 | 6.0 | 16.6 | 0 | 0 | 24.9 | 35.5 | 3.0 | 9.8 |
| Sep 26 | 5.0 | 8.1 | 4.4 | 15.2 | 0 | 0 | 30.0 | 37.7 | 3.5 | 9.6 |
| Sep 18 | 4.9 | 9.0 | 7.2 | 17.5 | 0 | 0 | 28.0 | 39.6 | 3.6 | 9.4 |


ACL Flu PCR tests results are consistent with **beginning of “Flu season”**

ACL COVAG and SCVPCR - Pos rate (%) - Dec 5, 2021




ACL SARS-CoV-2 positivity rate - trends up

CDC- Daily COVID-19 cases in US – Dec 02, 2021



CDC Covid positivity rate - trends down

Nov 27, 2021 – SARS-CoV-2 circulating in the US (~99.9% % Delta variants)



US vaccination status CDC | Data as of: Dec 2, 2021

464,445,580

Vaccines Administered

234,269,053

People who received at least one dose

197,838,728

People who are fully vaccinated*



70.6%

Percentage of the US population that has received at least one dose

59.6%


Percentage of the US population that has been fully vaccinated*

ACL (IL+WI) FLUPCR - Pos rate (5.5%) - Dec 5, 2021



ACL Flu positivity rate – **activity trends up** (111 pos /2031 samples tested)


Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, May 23, 2021 – November 27, 2021



CDC Midwest data as of: Nov 27, 2021



Percent of Respiratory Specimens Positive for Flu

2018-19 2019-20 2020-21 2021-22




2021-22 Influenza Season Week 47 ending Nov 27, 2021


ILI Activity Level



CSF targets positivity rate is 3.4%



The most prevalent GI bacterial target is - (Giardia 0.8%)



The most prevalent GI viral target is – (Adeno – 0.7%)

